MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: Functional andtherapeutic implications forgeneexpressionand the pathogenesis of hypertension

41Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Hypertension is acommonhereditary syndromewith unclear pathogenesis. ChromograninA(Chga), which catalyzes formation and cargo storage of regulated secretory granules in neuroendocrine cells, contributes to blood pressure homeostasis centrally and peripherally. Elevated Chga occurs in spontaneously hypertensive rat (SHR) adrenal glands and plasma, but central expression is unexplored. In this report, we measured SHR and Wistar-Kyoto rat (control) Chga expression in central and peripheral nervous systems, and found Chga protein to be decreased in the SHR brainstem, yet increased in the adrenal and the plasma. By re-sequencing, we systematically identified five promoter, two coding and one 3'-untranslated region (3'-UTR) polymorphism at the SHR (versus WKY or BN) Chga locus. Using HXB/BXH recombinant inbred (RI) strain linkage and correlations, we demonstrated genetic determination of Chga expression in SHR, including a cis-quantitative trait loci (QTLs) (i.e. at the Chga locus), and such expression influenced biochemical determinants of blood pressure, including a cascade of catecholamine biosynthetic enzymes, catecholamines themselves and steroids. Luciferase reporter assays demonstrated that the 3'-UTR polymorphism (which disrupts a microRNA miR-22 motif) and promoter polymorphisms altered gene expression consistent with the decline in SHR central Chga expression. Coding region polymorphisms did not account for changes in Chga expression or function. Thus, we hypothesized that the 3'-UTR and promoter mutations lead to dysregulation (diminution) of Chga in brainstem cardiovascular control nuclei, ultimately contributing to the pathogenesis of hypertension in SHR. Accordingly, we demonstrated that in vivo administration of miR-22 antagomir to SHR causes substantial (~18 mmHg) reductions in blood pressure, opening a novel therapeutic avenue for hypertension. © The Author 2013. Published by Oxford University Press. All rights reserved.

References Powered by Scopus

The human genome browser at UCSC

7774Citations
N/AReaders
Get full text

Predicting coiled coils from protein sequences

3625Citations
N/AReaders
Get full text

VISTA: Computational tools for comparative genomics

2089Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Impact of microRNAs on ischemic stroke: From pre- to post-disease

135Citations
N/AReaders
Get full text

Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases

121Citations
N/AReaders
Get full text

MicroRNAs and Endothelial (Dys) Function

103Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Friese, R. S., Altshuler, A. E., Zhang, K., Miramontes-Gonzalez, J. P., Hightower, C. M., Jirout, M. L., … O’Connor, D. T. (2013). MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: Functional andtherapeutic implications forgeneexpressionand the pathogenesis of hypertension. Human Molecular Genetics, 22(18), 3624–3640. https://doi.org/10.1093/hmg/ddt213

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

56%

Professor / Associate Prof. 8

22%

Researcher 7

19%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 14

45%

Medicine and Dentistry 8

26%

Agricultural and Biological Sciences 6

19%

Neuroscience 3

10%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 380

Save time finding and organizing research with Mendeley

Sign up for free